Choreo LLC’s Corcept Therapeutics CORT Stock Holding History

Choreo LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,659	Closed	-$257K	–	1629
2025 Q4	$257K	Sell	3,659 -107	-3%	-$8.4K	﹤0.01%	1310
2025 Q3	$313K	Sell	3,766 -329	-8%	-$23.8K	﹤0.01%	1203
2025 Q2	$301K	Sell	4,095 -289	-7%	-$21K	﹤0.01%	1170
2025 Q1	$501K	Sell	4,384 -203	-4%	-$12.4K	0.01%	830
2024 Q4	$233K	Sell	4,587 -535	-10%	-$28K	﹤0.01%	1334
2024 Q3	$239K	Buy	+5,122	New	+$182K	﹤0.01%	1357

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Choreo LLC's CORT Position: Q1 2026 in Review

Choreo LLC sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 3,659 shares — an estimated $257K sold.

Choreo LLC first reported a position in CORT in Q3 2024 and held it in 6 quarters. The position peaked at $501K in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Choreo LLC reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Choreo LLC sold 3,659 Corcept Therapeutics shares in Q1 2026, an estimated $257K.
Choreo LLC first reported a position in Corcept Therapeutics in Q3 2024 and held it in 6 quarters.
Choreo LLC's Corcept Therapeutics position peaked at $501K in Q1 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.